Spots Global Cancer Trial Database for sasanlimab
Every month we try and update this database with for sasanlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | NCT05665361 | Advanced Clear ... Papillary Renal... | Sasanlimab Palbocicilib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05259397 | Bladder Cancer | PF-07225570 sasanlimab | 18 Years - | Pfizer | |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | NCT05061537 | Renal Cell Canc... Melanoma Non-Small-Cell ... Hepatocellular ... Bladder Cancer Sarcoma Head and Neck C... Colorectal Canc... Ovarian Cancer Squamous Cell C... | PF-07263689 Sasanlimab | 18 Years - | Pfizer | |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | NCT06285097 | Neoplasms Non-small-cell ... Melanoma Squamous Cell C... Renal Cell Carc... Urothelial Carc... Colorectal Carc... Ovarian Carcino... | PF-07820435 Sasanlimab | 18 Years - | Pfizer | |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | NCT06285097 | Neoplasms Non-small-cell ... Melanoma Squamous Cell C... Renal Cell Carc... Urothelial Carc... Colorectal Carc... Ovarian Carcino... | PF-07820435 Sasanlimab | 18 Years - | Pfizer | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | NCT05935748 | ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas... | NKT2152 palbociclib sasanlimab | 18 Years - | NiKang Therapeutics, Inc. | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | NCT04165317 | Non-muscle Inva... | PF-06801591 Bacillus Calmet... | 18 Years - | Pfizer | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | NCT05665361 | Advanced Clear ... Papillary Renal... | Sasanlimab Palbocicilib | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
